Indicators on BCAT-IN-4 You Should Know
MI-CP151 was a section 1b randomised, double-blind, placebo managed, dose-escalation, multicentre study to evaluate a number of intravenous doses of sifalimumab, in Grownup people with dermatomyositis or polymyositis (NCT00533091). Main trial objectives have been To guage the security and tolerability of sifalimumab in dermatomyositis or polymyosit